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SUMMARY
Current therapies for multiple sclerosis (MS) are largely palliative, not curative. Mesenchymal stem cells (MSCs) harbor regenerative and
immunosuppressive functions, indicating a potential therapy for MS, yet the variability and low potency of MSCs from adult sources
hinder their therapeutic potential. MSCs derived from human embryonic stem cells (hES-MSCs) may be better suited for clinical treat-
ment of MS because of their unlimited and stable supply. Here, we show that hES-MSCs significantly reduce clinical symptoms and
prevent neuronal demyelination in amouse experimental autoimmune encephalitis (EAE) model of MS, and that the EAE disease-modi-
fying effect of hES-MSCs is significantly greater than that of human bone-marrow-derived MSCs (BM-MSCs). Our evidence also suggests
that increased IL-6 expression by BM-MSCs contributes to the reduced anti-EAE therapeutic activity of these cells. A distinct ability to
extravasate and migrate into inflamed CNS tissues may also be associated with the robust therapeutic effects of hES-MSCs on EAE.
INTRODUCTION
Multiple sclerosis (MS) is a chronic neuroinflammatory dis-
ease characterized by infiltration of peripheral immune
cells into the CNS through an impaired blood-brain barrier
(BBB) or blood-spinal cord barrier (BSCB), and loss of
myelin with accompanying scarring of axons (McFarland
and Martin, 2007). However, most current treatments for
MS only offer palliative relief without providing a cure,
andmany are also associated with adverse effects that limit
their long-term utility (Weber et al., 2012).
Transplantation of mesenchymal stem/stromal cells
(MSCs) for the treatment ofMShas emerged as an attractive
therapy due to the immunomodulatory and neuroregener-
ative properties of these cells (Auletta et al., 2012; Pittenger
et al., 1999) and their potential ability to repair the BBB
(Chao et al., 2009) with fewer side effects (Lalu et al.,
2012). MSC can home to injured tissues and exert thera-
peutic effects through the secretion of immunomodulatory
and trophic factors as well as through direct cell-cell con-
tact (Uccelli and Prockop, 2010). Importantly, allogeneic
MSCs generally do not provoke a strong host immune
response due to lack of expression of immune costimula-
tory receptors and low expression of major histocompati-
bility complex (MHC) class II antigens (Uccelli and
Prockop, 2010), raising the possibility that cells derived
from a single donor may be used to treat a large number
of patients.
Human adult-tissue-derivedMSCs have shown therapeu-
tic utility in experimental autoimmune encephalitis (EAE)
models of MS (Bai et al., 2009; Gordon et al., 2008, 2010;
Peron et al., 2012; Zhang et al., 2005) and in clinical trials
for MS patients (Connick et al., 2012; Karussis et al.,
2010; Mohyeddin Bonab et al., 2007; Yamout et al.,
2010); however, the large variability in the efficacy of
MSCs hinders their development as a standardMS therapy.
Extensive in vitro expansion of MSCs may diminish the
efficacy of these cells (Kyriakou et al., 2008), and MSCs
derived from younger cell sources (e.g., embryonic, fetal,
and umbilical cells) have higher in vitro proliferation
potential and can more readily differentiate (Barlow et al.,
2008; Giuliani et al., 2011). Thus, deriving MSCs from a
young and renewable (i.e., pluripotent) cell source, such
as human embryonic stem cells (hESCs), could (1) alleviate
the quantity and quality issues involved in the use of adult-
tissue-derived MSCs, (2) obviate the need for constant
donor recruitment, and (3) reduce the risk of pathogenicity
from the use of multiple donors.
Different groups have derived MSCs from hESCs (hES-
MSCs) with a morphology and immunophenotype similar
to those of BM-MSCs. Previously described derivation
methods involve coculturing with mouse OP9 cells and
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Figure 1. hES-MSCs Attenuate the Disease Score of MOG35-55/CFA-Immunized Mice
(A) Disease scores of MOG35-55/CFA-immunized mice treated with 10
6 hES-MSCs (CT2, H9, and MA09) or 106 parental hESCs at day 6
postimmunization. n = 5, ***p < 0.001 by Mann-Whitney. Error bar, SEM.
(B) Immunohistochemical detection of MBP (red) and CD3 for T cells (green) (a and b) and IBA1 for microglia (green) (c and d) on lumbar
spinal cord cross-sections from MOG35-55/CFA-immunized mice treated with either hES-MSC (a and c) or PBS (b and d). Scale bars, 250 mm
(a and b) and 120 mm (c and d).
(C) Relative fluorescent intensity measurements of MBP expression in digitally captured spinal cord hemi-sections. n = 4–6, **p < 0.02.
Error bar, SD. The regions shown are from the lumbar level of the spinal cord. Error bars indicate SD and the p value was determined using
two-tailed unpaired Student’s t test of the total fluorescence signal of each section.
(legend continued on next page)
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sorting, scraping, or handpicking of cells (Barberi et al.,
2005; Brown et al., 2009; Gruenloh et al., 2011; Hwang
et al., 2008; Olivier et al., 2006; Vodyanik et al., 2010),
which limits the efficiency and purity of the hES-MSCs,
as well as the ability to scale up their production. hES-
MSCs have been used in some disease models, such as
inflammatory bowel disease, lupus, and uveitis (Kimbrel
et al., 2014; Sa´nchez et al., 2011); however, no one has
shown whether hES-MSCs can be used to treat an EAE
model of MS or compared the immunosuppressive func-
tions of hES-MSCs and BM-MSCs. Here, using an improved
hemangioblast-enriching method (Lu et al., 2007), we
generated hES-MSCs from the MA09 ESC line (Kimbrel
et al., 2014) and multiple other hESC lines. We demon-
strate that these hES-MSC lines can effectively treat an
EAE model of MS and outperform multiple lines of BM-
MSCs in therapeutic activities.
RESULTS
hES-MSCs Attenuate EAE Disease in MOG35-55/CFA-
Immunized Mice when Administered either
Prophylactically or Therapeutically
In this study, we derived MSCs through a hemangioblast-
enriched, intermediate stage as described previously (Kim-
brel et al., 2014). We tested the reproducibility of this
method by generating independent MSC lines from four
different hESC lines: H9 (Thomson et al., 1998), CT2
(derived at UConn;Wang et al., 2009),MA09 (Klimanskaya
et al., 2006), and ES03-Envy (Envy, a GFP+ line derived at ES
International; Costa et al., 2005). These hES-MSC lines
expressed cell surface markers consistent with those of
adult human MSCs (Figure S1A available online) and
were capable of differentiating into osteocytes, adipocytes,
and chondrocytes (Figure S1B). We also confirmed that the
hES-MSCs were karyotypically normal for at least 12
passages (Figure S1C) and did not express telomerase
(Figure S1D).
We employed a standard EAE model of MS in which
C57BL/6 mice were immunized with an emulsion of
MOG35-55 peptide and complete Freund’s adjuvant (CFA)
to test the therapeutic utility of our hES-MSC lines. Six
days after immunization but prior to disease onset, mice
were injected with 13 106 hES-MSCs or PBS intraperitone-
ally (i.p.). hES-MSCs derived from three hESC lines (CT2,
MA09, and H9) all significantly attenuated the daily (Fig-
ure 1A), cumulative, and maximal disease scores (Fig-
ure S1E). H9 hES-MSCs also delayed the disease onset,
and MA09 hES-MSCs appeared to lower the disease inci-
dence (Figure S1E). However, mice injected with parental
hESCs (CT2)manifested high disease scores similar to those
of PBS controls (Figure 1A). To confirm the results, we
histologically analyzed microglial inflammatory activity
within the spinal cord. Immunostaining for ionized
calcium-binding adaptor molecule 1 (IBA1) revealed
inhibited development of microgliosis in MOG35-55/CFA-
immunized mice treated with hES-MSCs compared with
those treated with PBS (Figure 1B). Infiltration of CD3+
T cells into the spinal cord was decreased and the number
of interleukin-17 (IL-17)- and interferon g (IFNg)-express-
ing CD4+ Tcells in the CNS was also decreased by hES-MSC
treatment (Figures 1B, S1F, and S1G). Stronger immuno-
staining for myelin-binding protein (MBP) suggests that
demyelination was prevented in mice treated with hES-
MSCs (Figures 1B and 1C).
We also tested the effect of hES-MSC treatment on mice
that had already developed EAE (postonset). hES-MSCs
were injected on day 18 postimmunization, when all
mice had disease scores of 3. We observed a gradual decline
in disease scores from 3 down to an average score of 1.7 by
day 30 in hES-MSC-treated mice, whereas the PBS-treated
mice showed an average score of 2.8 by day 30 (Figure 1D).
Collectively, the data presented in Figure 1 show that hES-
MSCs can reproducibly decrease disease severity both
prophylactically and therapeutically in the mouse EAE
model.
Mitotically Arrested hES-MSCs Retain the EAE-
Inhibitory Effect
MSCs transplanted into animals may undergo malignant
transformation or support tumor growth formed by
host cells (Djouad et al., 2003; Wong, 2011). However,
since short-term cytokine secretion and cell-cell contact
may be sufficient to exert MSC functions (Uccelli and
Prockop, 2010), we hypothesized that mitotically arrested
MSCs may still execute a disease-modifying effect. To test
this, we irradiated hES-MSCs at 80 Gy immediately before
injecting cells into MOG35-55/CFA-immunized mice at
day 6 postimmunization. This irradiation regimen did
not significantly reduce the viability of hES-MSCs that
were replated and cultured for 48 hr in vitro (90% of
the cells were trypan-blue negative), but was sufficient
to completely attenuate cell proliferation as assessed by
(D) Disease scores of MOG35-55/CFA-immunized mice treated with 10
6 hES-MSCs 18 days postimmunization. n = 6, ***p < 0.001 by Mann-
Whitney. Error bar, SEM. At day 17 postimmunization, all mice with a disease score of 3 were pooled into a single group and then randomly
assigned to either the PBS-treatment group or the hES-MSC-treatment group. Mice that were immunized but did not show a disease score of
3 on day 17 were removed from the study.
See also Figure S1.
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bromodeoxyuridine (BrdU) incorporation during this same
time period (Figure 2A). Mice that received 23 106, but not
1 3 106, irradiated cells showed a similar reduction in EAE
disease severity asmice who received 13 106 nonirradiated
hES-MSC (Figures 2B and S2A). To determine the lifespan of
irradiated hES-MSC in vivo, we established a CT2 hESC
clone with constitutive expression of luciferase in the
hESCs and subsequent hES-MSCs (Figure S2B) by
Figure 2. Mitotically Arrested hES-MSCs Retain the EAE-Inhibitory Effect
(A) Nonirradiated or irradiated hES-MSCs (1 3 105) were cultured in vitro for 48 hr in the absence (gray line) or presence (black line) of
BrdU. The percentage of proliferating cells, as determined by flow-cytometry staining for BrdU+ cells, is indicated.
(B) Disease scores of MOG35-55/CFA-immunized mice treated at day 6 with PBS, 10
6 nonirradiated or 23 106 irradiated hES-MSCs (MA09);
n = 4, ***p < 0.001 by Mann-Whitney for comparison with the PBS control. Error bar, SEM. The table below shows a comparison of
cumulative disease score (Cum. D.S.), maximum disease score (Max. D.S.), disease incidence, and disease onset day.
(C) Nonirradiated (left) and irradiated (right) luciferase-expressing hES-MSCs (CT2) were tracked in MOG35-55/CFA-immunized mice by
in vivo bioluminescence imaging using the Xenogen IVIS 100 system.
See also Figure S2.
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transducing the cells with a lentiviral vector (Pomper et al.,
2009). Using these luciferase-expressing hES-MSCs, we
found that both irradiated and nonirradiated hES-MSCs
had roughly the same lifespan of at least 7 days in wild-
type mice as determined by whole-body bioluminescence
imaging (Figure 2C).
Teratoma formation is another concern for any cells
differentiated from pluripotent cells. To assess this risk,
we injected hES-MSCs into immunodeficient SCID-beige
mice at 1 3 106 cells/mouse, and found no tumor forma-
tion at the injection sites within 2 months, whereas tera-
tomas formed in mice injected with the same dose of
parental hESCs (data not shown).
hES-MSCs Have Stronger EAE-Inhibitory Effects than
BM-MSCs
Next, we compared hES-MSCs and BM-MSCs in the pro-
phylactic EAE model. We derived MSCs from six different
BM donors (four from frozen monocytes [MNCs] and two
from fresh BM) and obtained two BM-MSC lines at passage
1 from the Texas A&MMSC repository. We tested BM-MSC
lines anywhere from passage 2 to 4 and found that none of
them could consistently attenuate EAE disease scores of
MOG35-55/CFA-immunized mice, as shown in Figures 3A
(BM-MSC#1–3), 3B (BM-MSC#4), 6 (GFP-expressing BM-
MSC#5), and S3F (BM-MSC#7-8). Of note, one BM-MSC
line (BM-MSC#6, from Texas A&M) showed moderate but
significant disease-modifying effects (Figure 3C) at passage
2 relative to control PBS-treated mice (p < 0.001), but these
effects were gone at passage 4 (see Figure 5F). This is in
marked contrast to the four independent hES-MSC lines
that all showed a strong disease-inhibitory effect when
tested up to passage 5, as shown in Figures 1A (H9, CT2,
and MA09) and 6 (GFP-expressing Envy).
EAE/MS is accompanied by infiltration of reactive T cells
into the CNS (McFarland andMartin, 2007).We found that
hES-MSC-injected mice had significantly fewer CD4+ and
CD8+ T cell infiltrates in the CNS, including Th1 and
Th17 CD4+ subsets, than PBS-treated MOG35-55/CFA-
immunized mice (Figures 3D, S1F, and S1G), whereas
parental hESC line CT2-treatedmice had levels comparable
to those in controls (Figure S1F). In contrast, BM-MSC-
treated mice actually displayed significantly more CD4+
and slightly more CD8+ T cell infiltrates than PBS-treated
MOG35-55/CFA-immunized mice (Figure 3D, first two
panels). This included similar or greater Th1 numbers
and consistently greater Th17 numbers compared with
the controls (Figure 3D, last two panels). Reduced
FluoroMyelin staining of MBP in the spinal cord of both
PBS- and BM-MSC-treated mice suggests severe demyelin-
ation, whereas MBP levels were preserved in the spinal
cord of hES-MSC-treated mice (Figure 3E). The damaged re-
gions in BM-MSC-treated mice also show a high number of
DAPI-positive cells (Figure 3E), suggesting more inflamma-
tory cell infiltration. To determine whether the reduced
FluoroMyelin staining in the BM-MSC-treated mice was
due to reduced levels of myelin, loss of entire axons, or
inflammatory infiltrate blocking myelin staining, we per-
formed costaining for MBP and neurofilament (NF) on
day 32 lumbar spinal cord cross-sections. Quantification
of MBP-positive areas again revealed significantly lower
levels ofmyelination in BM-MSC-treatedmice as compared
with hES-MSC-treated ones, whereas NF staining revealed
similar numbers of axons in both groups (Figures S3A–S3E).
Considering the important role of regulatory T cells (Treg
cells detected as CD4+, Foxp3+, and CD25+) in suppressing
inflammation, we examined the ratio of Treg cells among
infiltrated CD4+ Tcells in the CNS, and found no difference
in hES-MSC-treated versus control MOG35-55/CFA-immu-
nized mice (Figure S3G). This is similar to a previous report
(Zappia et al., 2005). In vitro, both hES-MSCs and BM-
MSCs increased Treg cell proliferation in the presence of
IL-2, but there was no remarkable difference between the
two groups (Figure S3H). This suggests that enhanced Treg
cell proliferation is a common response to both hES-
MSCs and BM-MSCs, but is not necessarily a contributor
to their divergent effects in the in vivo EAE model.
Analyzing MSC Effects on T Cell Functions: hES-MSCs
Show Stronger Inhibition of Th1 Differentiation than
BM-MSCs
We next compared hES-MSCs and BM-MSCs for their
ability to inhibit T cell proliferation in vitro, using mixed
leukocyte reaction (MLR) assays. We incubated carboxy-
fluorescein succinimidyl ester (CFSE)-labeled mouse naive
T cells isolated from lymph nodes with increasing amounts
of BM-MSCs or hES-MSCs. Both types of MSCs inhibited
CD4+ and CD8+ T cell proliferation in response to a con-
stant amount of anti CD3/anti-CD28 stimulation to similar
degrees (Figure 4A). Likewise, BM-MSCs and hES-MSCs
similarly inhibited human peripheral blood mononucle-
ated cell (PBMC) proliferation induced in response to
phytohemagglutinin (PHA) over a range of PBMC/MSC
ratios (Figure 4B). Together, these data suggest that BM-
MSCs and hES-MSCs display similar inhibitory effects on
T cell proliferation in vitro.
Since MOG35-55/CFA-immunized mice treated with BM-
MSCs had more Th1 and Th17 cell infiltration in the CNS
thanmice treated with hES-MSC (Figure 3D), we examined
these T cell subtypes in vitro in the presence or absence of
hES-MSCs and BM-MSCs. Under the Th1 condition, differ-
entiation of naive CD4+ T cells into Th1 (CD4+/IFNg+) cells
was reduced by hES-MSCs, but was unaffected or even
enhanced by different BM-MSC lines (Figure 4C, upper
panels). Interestingly, even the BM-MSC line (BM-
MSC#6) that gave a modest but significant therapeutic
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Figure 3. hES-MSCs Have a Stronger EAE-Inhibitory Effect In Vivo than BM-MSCs
(A–C) Disease scores of MOG35-55/CFA-immunized mice treated with PBS, 10
6 BM-MSCs, or 106 hES-MSCs (MA09) at day 6. n = 4–5 per group,
***p < 0.001 by Mann-Whitney for comparison with the PBS control. Error bar, SEM. The table below shows a comparison of cumulative
disease score (Cum. D.S.), maximum disease score (Max. D.S.), disease incidence, and disease onset day.
(D) Total numbers of CD4+, CD8+, Th1, and Th17 cells in the CNS of MOG35-55/CFA-immunized mice treated with PBS, BM-MSCs, or hES-MSCs
on day 32 postimmunization. Lymphocytes purified from the CNS were analyzed via flow cytometry for numbers of CD4+ and CD8+ cells
(left two panels) or IL-17+ and IFNg+ cells (intracellular stained) poststimulation with 12-O-tetradecanoylphorbol-13-acetate (TPA)
and ionomycin (right two panels). n = 4, *p < 0.05, **p < 0.01. Error bar, SD; p values were determined using two-tailed unpaired Student’s
t test.
(legend continued on next page)
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response in the prophylactic EAE model could not effec-
tively reduce Th1 differentiation in this in vitro assay
(Figure 4C, upper last panel). Under the Th17 differentia-
tion condition, both hES-MSCs and BM-MSCs reduced
the differentiation of Th17 (CD4+/IL17+) cells (Figure 4C,
lower panels). However, under the same Th17-inducing
conditions, BM-MSCs, but not hES-MSCs, significantly
increased the percentage of IFNg+/IL17 (i.e., Th1) cells
(Figure 4C, lower panels). Collectively, these results show
that hES-MSCs effectively dampen differentiation of both
Th1 and Th17 in vitro, and, surprisingly, BM-MSCs
promote Th1 differentiation under a Th17-inducing
environment.
BM-MSCs Express Higher Levels of IL-6 than hES-MSC,
and IL-6 Blockage Enhances the Disease-Modifying
Effects of BM-MSCs in the EAE Model
Many factors have been reported to mediate the immuno-
modulatory and/or neuroprotective effects of MSCs
(Uccelli and Prockop, 2010). We conducted a microarray
analysis to identify differences in the expression of these
factors between BM-MSCs and hES-MSCs. The overall
expression profiles of the hES- and BM-MSC samples were
similar (data not shown); however, a small set of genes
was expressed differentially. Among these, IL6 appeared
to be much more highly expressed in BM-MSCs than in
hES-MSCs. Multiple methods, including quantitative RT-
PCR (qRT-PCR; Figure 5A), intracellular flow cytometry
(Figure 5B), and cytokine antibody arrays (Figure 5C),
confirmed this finding.
Upon IFNg stimulation, the percentage of IL-6-express-
ing hES-MSCs did not change; however, the percentage of
IL-6-expressing BM-MSC nearly doubled (Figure 5D). We
also tested MSC production of IL-6 following coculture
with stimulated PBMC/T cells, as the latter produce high
levels of IFNg and TNF-a upon stimulation. IL-6 mRNA
expression levels increased for both BM-MSCs and hES-
MSCs after coculture, yet the levels in BM-MSC were still
R10 times higher than in hES-MSCs (Figure S4A). This
large difference in IL-6 secretion was a rather unique obser-
vation because the expression levels of other secreted cyto-
kines did not differ dramatically between the two cell types
(data not shown).
Since IL-6 has been found to enhance T cell differentia-
tion (Dienz and Rincon, 2009), we sought to determine
the effects of MSC-secreted human IL-6 on mouse T cell
differentiation. First, we confirmed that human IL-6 works
just as well asmouse IL-6 at an equivalent dose for directing
mouse Th17 differentiation (Figure S4B). Next, under Th0
conditions (i.e., without any mouse cytokines), we found
that an anti-human-IL-6 neutralizing antibody with no
mouse cross-reactivity (clone MQ2-13A5) reduced the
Th1-promoting effects of BM-MSCs on mouse T cells
by 23%–50% (Figure 5E). Lastly, we observed that
MOG35-55/CFA-immunized mice treated with human BM-
MSCs plus the same anti-hIL-6 antibody showed a sig-
nificant reduction in EAE disease severity relative to the
control group (Figure 5F). This effect was specific for IL-6
produced by the BM-MSCs, as IL-6 antibody alone (no
MSCs) or BM-MSCs plus isotype control antibody failed
to reduce the EAE disease score significantly. These data
suggest that high IL-6 expression by human BM-MSCs
contributes to the inability of these cells to modulate EAE
disease severity.
Both hES-MSCs and BM-MSCs Home to the Spinal
Cord, but Only hES-MSCs Successfully Extravasate
into Inflamed Tissue
To determine whether hES- and BM-MSCs home to the
injured CNS, we used the constitutively GFP-expressing
hESC line ‘‘Envy’’ and GFP-labeled human BM-MSCs (Hof-
stetter et al., 2002) in MOG35-55/CFA-immunized mice.
Cells were injected on day 6 after immunization and spinal
cords were analyzed 8 days later (day 14 postimmuniza-
tion), a time point when disease scores for the GFP+ BM-
MSC-injected mice and PBS controls were 1.5–2.0, and
scores for the GFP+ hES-MSC were effectively 0 (Figure 6A).
Both BM-MSCs and hES-MSCs homed to the spinal cord in
mice subjected to EAE (Figure 6B), yet the vascular associa-
tion patterns of the two types of MSCwere vastly different.
At day 14, GFP+ hES-MSCs were immunolocalized in the
parenchyma adjacent to spinal cord venules, indicating
the ability of these cells to penetrate and move beyond
the vasculature to enter the parenchyma (Figure 6B, top
row). In marked contrast, GFP+ BM-MSCs appeared to
remain closely associated with the parenchymal vessels,
seemingly trapped inside the microvascular lumen and/or
confined to the perivascular space, and incapable of
breaching the bipartite complex of endothelial and paren-
chymal basement membranes (Owens et al., 2008; Paul
et al., 2014) to enter the CNS tissue (Figure 6B, second
row). This apparent retarded migration of BM-MSCs per-
sisted even at day 18, when the disease is more severe
and both tight junctions and the basement membrane
complex of the BBB have been shown to be grossly disrup-
ted (Figure 6B, third row) (Paul et al., 2013, 2014). No GFP
(E) Qualitative analysis of myelin content in spinal cord cross-sections of MOG35-55/CFA-immunized mice treated with PBS, BM-MSCs, or
hES-MSCs using FluoroMyelin staining (green) and counterstained with DAPI (blue) for infiltration of nucleated cells. Scale bar, 350 mm.
The regions shown are from the lumbar level of the spinal cord.
See also Figure S3.
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Figure 4. Effects of hES-MSCs and BM-MSCs on T Cell Functions In Vitro
(A) hES-MSCs (MA09) or hBM-MSC#7 were cocultured with 1 3 105 CFSE-labeled mouse lymphocytes stimulated with anti-CD3/CD28 at
various MSC/lymphocyte ratios. After 3 days, the proportion of proliferating CD4+ (left panel) or CD8+ (right panel) T cells was measured by
CFSE dilution using flow cytometry. The percent inhibition of T cell proliferation is relative to T lymphocytes stimulated in the absence of
MSCs. Lymphocytes from three individual mice were tested and results are average ± SD.
(B) Mitotically inactivated hES-MSCs (MA09) or BM-MSCs were incubated with CFSE-labeled human PBMC at the indicated ratios
and stimulated with 2.5 ng/ml PHA. Bars represent the average of three different BM-MSC lines and two independent hES-MSC (MA09)
clones ± SD.
(C) hES-MSCs (MA09) or BM-MSCs were incubated with mouse naive CD4+ T cells at a ratio of 1:10, followed by Th1 or Th17 differentiation
for 5 days. IFNg+ and IL-17+ CD4+ T cells were detected via intracellular flow cytometry staining after TPA/ionomycin stimulation. Data
represent four independent experiments.
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signals could be detected in control mice receiving PBS
injection alone (Figure 6B, bottom row). Movies S1 and
S2, whichweremade from confocal z-stack reconstructions
of the data sets in Figure 6B, provide a magnified 3D
perspective of hES-MSC and BM-MSC distributions, respec-
tively. Figure 6C shows a schematic detailing the regions of
spinal cord selected for analysis in Figure 6B.
DISCUSSION
In this study, we have shown that multiple hES-MSC lines
significantly attenuated disease scores in a mouse EAE
model of MS. In stark contrast, only one out of eight
independently derived human BM-MSC lines displayed a
marginal effect in the prophylactic-treatment EAE model.
Our analysis of IL-6 expression and migration of the
MSCs suggests that the superior disease-altering effects of
hES-MSCs may be related in part to the lower expression
of IL-6 and the greater ability of hES-MSCs to extravasate
the BBB/BSCB and migrate into inflamed CNS tissue rela-
tive to BM-MSCs.
In examining the effects of hES-MSCs on EAE induction,
we observed that preonset treatment of MOG35-55/CFA-
immunized mice was more effective in attenuating disease
scores than postonset treatment. This is not surprising,
since preonset treatment begins before the development
of severe demyelination, axonal damage, or inflammatory
cell infiltration. Costaining for MBP and NF in day 32
lumbar spine sections of treated animals showed that
hES-MSC treatment protected against demyelination
without affecting the number of surviving axons. These
results do not rule out the possibility that hES-MSCs may
also contribute to remyelination of axons that have already
lost their myelin. This remains to be elucidated by further
investigations examining whether and how hES-MSCs
may contribute to neural regeneration. Future studies in
the postonsetmodel will also be needed to address whether
larger doses and/or repeated injections of cells could
enhance the therapeutic effects. Of note, irradiated hES-
MSCs were also effective in reducing the EAE disease score
and had the same lifespan in vivo as their nonirradiated
counterparts. Thus, irradiation of cells may provide an
important clinical benefit by reducing concerns about the
tumorigenic potential of MSCs.
Themuted in vivo efficacy of BM-MSCs that we observed
is consistent with previous reports that showed only mild
(Gordon et al., 2008; Zhang et al., 2005) or negligible
(Payne et al., 2013) effects in the EAE mouse model. Inter-
estingly, BM-MSC#6, the BM-MSC line that caused a
modest reduction in EAE disease scores in the preonset
model at passage 2 (Figure 3C), failed to show any thera-
peutic effects when used at passage 4 during the anti-iL-6
antibody experiment (Figure 5F). On the other hand,
hES-MSCs consistently resulted in large reductions in the
disease score of MOG35-55/CFA-immunized mice when
used frompassage 2 to 5. This indicates that the therapeutic
capacity of BM-MSCs may be more vulnerable to extended
in vitro culture than that of hES-MSCs.
It has been reported that BM-MSCs derived from frozen
MNCs have less immunosuppressive effects than those
derived from fresh MNCs (Samuelsson et al., 2009). We
derived different BM-MSC lines from both frozen MNCs
and fresh (never frozen) whole BM. Both types had
similarly negligible effects in the EAE model when admin-
istered prophylactically (Figures 3A, 3B, and S3F). One BM-
MSC line (#8), derived from fresh BM, did show a modest
efficacy in the EAE model when administered postonset
(Figure S3I), but this effect was not as great as that of hES-
MSCs (Figure 1D). These data suggest that variability
among human BM-MSC lines derived from different do-
nors could influence the efficacy of these cells, whereas
hES-MSC lines consistently exhibit a greater EAE-inhibi-
tory effect than human BM-MSC lines.
In this study, we found that IL-6 was much more highly
expressed in BM-MSCs than in hES-MSCs in both the basal
and IFNg-stimulated states. Elevated IL-6 levels have been
found in blood and brain tissue fromMSpatients (Patanella
et al., 2010), and site-specific production of IL-6 in the CNS
can enhance inflammation in EAE (Quintana et al., 2009).
Mice lacking IL-6 receptor a are resistant to EAE (Leech
et al., 2013), and an IL-6-neutralizing antibody can reduce
symptoms in EAE mice (Gijbels et al., 1995). Thus, higher
levels of human IL-6 secretion by BM-MSCs relative to
hES-MSCs may contribute to functional differences in the
treatment of EAE. This idea is supported by our data
showing that blocking human IL-6 with a neutralizing
antibody partially rescues the disease-modifying effects of
BM-MSC in the EAE model (Figure 5F). It is important to
note that the anti-hIL-6 antibody in this study does not
inhibit the endogenous mouse IL-6. This suggests that
human IL-6 produced by the BM-MSCs may act in an auto-
crine or paracrine manner on the BM-MSCs themselves
and/or on surrounding cells, with the net effect of limiting
BM-MSC therapeutic activity in EAE.
Recent reports have noted that MSCs can actually
promote the differentiation of proinflammatory T cells in
certain permissive environments (Carrio´n et al., 2011;
Darlington et al., 2010). Consistently, in vivo and in
comparison with PBS controls, we observed reduced CNS
infiltration of Th1 and Th17 cells with hES-MSC treatment,
but increased CNS infiltration of Th1 and Th17 cells with
BM-MSC treatment. In vitro and in contrast to hES-MSCs,
we found that BM-MSCs skewed T cell differentiation to a
Th1 phenotype under both Th0 (nonpolarizing) and
Th17 conditions. It is possible that certain factors that are
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highly produced by human BM-MSCs, but not hES-MSCs,
can trigger Th1 differentiation, thus overriding Th17 differ-
entiation under defined in vitro conditions (Lazarevic
et al., 2011). An anti-human IL-6 antibody was able to
partially reverse the effect under Th0 conditions (Figure5E),
but not Th17 conditions (data not shown), presumably
because the presence of abundant exogenous mouse IL-6,
which was added for Th17 induction, could not be neutral-
ized by the anti-human IL-6 antibody. Together, these
results suggest that high IL-6 secretion by BM-MSCs may
impact the local cytokine milieu and augment the overall
inflammatory response, resulting in a striking difference
in Th1/Th17 CNS infiltration between hES-MSC- and
BM-MSC-treated mice.
Lastly, we observed that both GFP-labeled hES-MSCs and
BM-MSCs homed to the CNS microvasculature, but only
hES-MSCs that showed a high therapeutic potential had
the capacity to effectively extravasate and migrate into
the parenchyma. This raises the possibility that therapeutic
efficacy and MSC extravasation are somehow mechanisti-
cally linked. Such a therapeutic requirement for MSCs to
extravasate during EAE is consistent with evidence that
these cells can downregulate proinflammatory effector
functions of parenchymal microglia (Figure 1B; Lee et al.,
2012; Sheikh et al., 2011). The lack of penetration into
the CNS tissue by BM-MSCs was further remarkable in
that it persisted through late disease, a time when severe
BBB disruption has been shown to occur (Paul et al.,
2013, 2014). Since such a compromised BBB might be ex-
pected to facilitate cellular entry during EAE (Lanz et al.,
2013), this suggests that hES-MSCsmight uniquely express
specific transendothelial migratory signals or properties.
BM-MSCs, in turn, might lack one or more of the minimal
requirements for effective migration across even a structur-
ally attenuated CNS microvascular endothelium and/or
surrounding basementmembrane complex. It is significant
that in vitro culture and expansion of MSCs have both
been implicated as factors that impair homing and transen-
dothelial migration (De Becker et al., 2007; Rombouts and
Ploemacher, 2003). A priori, BM-MSCs could be more sen-
sitive to these factors than hES-MSCs, which could at least
partially explain the differences in therapeutic efficacy
observed between the twoMSC types. Determining the dy-
namic changes and differences in expression of adhesion
molecules, chemokines/chemokine receptors, and matrix
metalloproteinase between hES-MSCs and BM-MSCs
in situ will be critical for delineating the molecular require-
ments for MSC extravasation and efficacy (De Becker et al.,
2007; Teo et al., 2012). In situ gene-expression profiling of
both MSC types is currently under investigation and
should shed further light on the mechanism(s) responsible
for the unique therapeutic efficacy of hES-MSCs in EAE.
EXPERIMENTAL PROCEDURES
Culture of hESCs and Generation of hES-MSCs
hESC lineswere cultured either onMatrigel in TeSR1mediumor on
mouse embryonic fibroblasts in Dulbecco’s modified Eagle’s
medium/F12 + 20% knockout serum replacement + 10 ng/ml basic
fibroblast growth factor. hES-MSCs were generated as described
previously (Kimbrel et al., 2014). Only hES-MSCs at %5 passages
were used throughout the study. The use of hESCs in this study
was approved by the Stem Cell Research Oversight Committee of
the University of Connecticut (#2012-005).
Figure 5. BM-MSCs Express Higher Levels of IL-6 than hES-MSCs, and a Neutralizing IL-6 Antibody Reduces the Influence of BM-
MSCs on T Cells and Disease Scores
(A) qRT-PCR for IL-6 in BM-MSCs versus hES-MSCs. Bars represent the average of three independent experiments ± SD. *p < 0.05 (the
p value was determined using two-tailed unpaired Student’s t test).
(B) Intracellular flow cytometry showing the percentage of IL-6-expressing cells (black line) and isotype control (gray line) among BM-
MSC from three different donors and hES-MSCs from three hESC lines (MA09, CT2, and H9).
(C) Cytokine antibody arrays showing the level of IL-6 and IL-8 proteins in conditioned medium from hES-MSC or BM-MSC cultures.
Cytokine antibodies and controls are spotted in duplicate and labeled next to the corresponding spots. Images are representative of at
least five independent experiments.
(D) Intracellular flow cytometry showing the percentage of IL-6-expressing cells (black line) and isotype control (gray line) among hES-
MSCs or BM-MSCs treated ± 10 ng/ml IFNg for 12 hr. NC, negative control.
(E) Intracellular flow cytometry measuring the percentage of CD4+ and IFNg+ mouse T cells arising from naive T cells after coculture with
hES-MSC (MA09) or BM-MSCs from three different donors under Th0 conditions. The MSC/T cell ratio was 1:10. IgGk isotype control (upper
panels) or anti-human IL-6 neutralizing antibody (clone MQ2-13A5) was added to determine the effect of blocking IL-6 on BM-MSC-
induced production of IFNg from T cells (i.e., Th1 differentiation) (lower panels).
(F) Mean disease scores of mice immunized with MOG35-55 and treated with PBS or 1 3 10
6 human BM-MSC on day 6. Anti-human IL-6
neutralizing antibody (clone MQ2-13A5, 12.5 mg/kg/day), IgGk isotype control antibody (12.5 mg/kg/day) or PBS was administered i.v.
on days 6 and 7. ***p < 0.001 by Mann-Whitney for BM-MSC#6+anti-iL-6 versus PBS control (n = 5 per group). Error bar, SEM. The table on
the right shows a comparison of cumulative disease score (Cum. D.S.), maximum disease score (Max. D.S.), disease incidence, and disease
onset day.
See also Figure S4.
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Animal Model of MS
The mouse EAE model was induced as previously described
(Stromnes and Goverman, 2006). In brief, C57BL/6mice were sub-
cutaneously injected with an emulsion of MOG35-55 peptide, CFA,
and pertussis toxin contained in the EAE induction kit fromHooke
Laboratories (Cat. No. EK-0114). BM-MSCs or hES-MSCs at 13 106
cells/mouse or PBS (a vehicle control) were i.p. injected on day 6
(for preonset) or 18 (for postonset) after the immunization. Disease
scorewasmonitored every day for up to 31 ormore days as follows:
0, no sign of disease; 1, loss of tone in the tail; 2, partial hind limb
paralysis; 3, complete hind limb paralysis; 4, front limb paralysis;
and 5, moribund (Stromnes and Goverman, 2006). For some
experiments, cumulative and maximal disease scores were also
calculated, and disease incidence and disease onset day were re-
corded. Injection and scoring were performed double-blinded in
Figure S3F. All animal studies were approved by and performed
in accordance with policies of the Institutional Animal Care and
Use Committee of the University of Connecticut Health Center.
Tracking of GFP+ MSCs in Perivascular Regions in
the CNS
Spinal cord tissue was prepared as described previously (Paul et al.,
2013). In brief, after perfusion/fixation, spinal cords were har-
vested by laminectomy and cryosectioned for immunostaining.
Anti-GFP-Alexa 488, anti-CD31 (BD Bioscience), and Alexa 555
secondary antibody (Life Technologies) were used to detect GFP+
and endothelial cells, and DRAQ5 (Biostatus) was used to visualize
the nuclei. Sections were then mounted in Mowiol and confocal
z-stacks were acquired at 1 mm increments between z slices,
following a multitrack scan, using a Zeiss LSM 510 Meta confocal
microscope. Images were analyzed with Imaris suite version 7.1
software (Bitplane). The GFP channel was isosurface rendered to
provide better spatial perspective for visualizing GFP+ cells.
Statistical Analysis
The EAE clinical disease scores for each group were graphed as the
mean ± SEM for each day of the study. Differences in EAE disease
scores between groups were analyzed using the nonparametric
Mann-Whitney unpaired U test, and individual time-point differ-
ences were analyzed using two-way ANOVA with Bonferroni’s
posttest. Percentage data for CNS-infiltrated T cells were arcsine
transformed prior to analysis. EXCEL and Prism 6.0 (GraphPad)
software was used for statistical analysis, and p < 0.05 was consid-
ered to be statistically significant (*p < 0.05, **p < 0.01, ***p <
0.001).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental
Procedures, four figures, and two movies and can be found
with this article online at http://dx.doi.org/10.1016/j.stemcr.
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